On the other hand, incretin-based therapy has several potential sites of action for the treatment of type 2 diabetes ranging from increasing insulin secretion, reducing glucagon secretion, and regulating glucose control [2]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.